TITLE

Diamyd Climbs on $625M Type I Diabetes Deal

PUB. DATE
June 2010
SOURCE
Bioworld Week;6/28/2010, Vol. 18 Issue 26, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the deal to develop the Type I diabetes, entered by Diamyd Medical AB in Sweden.
ACCESSION #
51924583

 

Related Articles

  • Diamyd Eyes Spring Start for Phase III Diabetes Trial. Sheridan, Cormac // BioWorld International;2/20/2008, Vol. 13 Issue 8, p2 

    The article reports on the plan by Stockholm, Sweden-based Diamyd Medical AB to begin a Phase III clinical trial of its therapeutic vaccine for Type I diabetes in spring. The U.S. Food and Drug Administration (FDA) questioned a minor aspect of the vaccine's manufacturing process. According to...

  • Diamyd Medical: Quarterly Report II 10/11.  // Biomedical Market Newsletter;5/14/2011, p165 

    The article offers information on the quarterly report II of the company, Diamyd Medical AB for the year 2011 in the U.S. It mentions that the interest of the company is high and the company has more than 6,000 shareholders. It states that the company focuses on the development of...

  • Diamyd Stock Plunges 85% on Phase III Diabetes Miss. Sheridan, Cormac // BioWorld Today;5/10/2011, Vol. 22 Issue 90, p1 

    The article reports that share price in Diamyd AB dropped by 85 percent following news that its immunotherapy treatment for Type I diabetes called Diamyd failed to reach the primary endpoint of a European Phase III trial. Diamyd is a therapeutic vaccine that is a recombinant type of glutamic...

  • Diamyd initiates European submission for Phase III diabetes vaccine.  // PharmaWatch: Biotechnology;Mar2008, Vol. 7 Issue 3, p10 

    The article focuses on the application submission procedure initiated by Diamyd Medical AB to start the European Phase III studies of its diabetes vaccine. The submission has been sent to the Swedish Medicinal Products Agency. Moreover, the study proposed to include about 300 patients at 30-50...

  • Diamyd Medical: TrialNet Presents Results From a Study with Diamyd(r).  // Biomedical Market Newsletter;7/5/2011, p541 

    The article reports that the results of the American research consortium Type 1 Diabetes TrialNet was presented by Diamyd Medical AB at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California on June 27, 2011. It says that Diamyd® is a diabetes therapy...

  • Diamyd Medical: Diamyd Presents Detailed Results of European Phase III Study.  // Biomedical Market Newsletter;7/5/2011, p441 

    The article offers information on the details of European Phase III study of DIAMYD Medical AB regarding the efficacy of their antigen-based diabetes therapy Diamyd®, presented at the 71st Scientific Sessions of the American Diabetes Association in San Diego, California on June 28, 2011. It...

  • Diamyd Files IND: Phase III Vaccine Could Slow Diabetes. Osborne, Randall // BioWorld Today;12/26/2007, Vol. 18 Issue 248, p1 

    The article discusses the application for a Phase III trial of the glutamic acid decarboxylase 65 (GAD65) vaccine from Diamyd Medical AB. According to the company, the vaccine will be used to save insulin-making beta cells in Type 1 diabetics. In addition, the vaccine will also help stop or slow...

  • Johnson & Johnson Drops Diamyd Type I Diabetes Program. Sheridan, Cormac // BioWorld International;6/8/2011, Vol. 16 Issue 23, p4 

    The article reports on the decision of Johnson & Johnson to drop its shares in the Phase III Diamyd Type I Diabetes Program of Diamyd Medical AB. Johnson & Johnson acting chief executive officer (CEO) Peter Zerhouni says that the decision was made after the company realized that the results of...

  • CLINIC ROUNDUP.  // BioWorld Today;1/23/2008, Vol. 19 Issue 15, p8 

    This section offers news briefs concerning biopharmaceutics. Ambrilia Biopharma Inc. garnered positive preliminary Phase III results for its prolonged release formulation of Octreotide in acromegaly patients. Arpida Ltd. started patient screening for enrollment into its Phase III study of its...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics